Abstract:Abstract Background Plasmodium falciparum , the parasite causing malaria, affects populations in many endemic countries threatening mainly individuals with low malaria immunity, especially children. Despite the approval of the first malaria vaccine MosquirixTM and very promising data using cryopreserved P. falciparum sporozoites (PfSPZ), further research is needed to elucidate the mechanisms of humoral immunity for the development of next-generation vaccines and alternative malaria therapies including antibody therapy. A high prevalence of antibodies against AMA1 in immune individuals has made this antigen one of the major blood-stage vaccine candidates. Material and methods Using antibody phage display, an AMA1-specific growth inhibitory human monoclonal antibody from a malaria-immune Fab library using a set of three AMA1 diversity covering variants (DiCo 1–3), which represents a wide range of AMA1 antigen sequences, was selected. The functionality of the selected clone was tested in vitro using a growth inhibition assay with P. falciparum strain 3D7. To potentially improve affinity and functional activity of the isolated antibody, a phage display mediated light chain shuffling was employed. The parental light chain was replaced with a light chain repertoire derived from the same population of human V genes, these selected antibodies were tested in binding tests and in functionality assays. Results The selected parental antibody achieved a 50% effective concentration (EC 50 ) of 1.25 mg/mL. The subsequent light chain shuffling led to the generation of four derivatives of the parental clone with higher expression levels, similar or increased affinity and improved EC 50 against 3D7 of 0.29 mg/mL. Pairwise epitope mapping gave evidence for binding to AMA1 domain II without competing with RON2. Conclusion We have thus shown that a compact immune human phage display library is sufficient for the isolation of potent inhibitory monoclonal antibodies and that minor sequence mutations dramatically increase expression levels in Nicotiana benthamiana . Interestingly, the antibody blocks parasite inhibition independently of binding to RON2, thus having a yet undescribed mode of action.

Somatic hypermutation-mediated paratope flexibility improves the cross-reactivity of human malaria antibodies

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope

Plasmodium Falciparum-Specific IgM B Cells Dominate in Children, Expand with Malaria and Produce Parasite Inhibitory IgM

Atypical B Cells Up-Regulate Costimulatory Molecules During Malaria and Secrete Antibodies with T Follicular Helper Cell Support

Autoantibodies Inhibit Plasmodium Falciparum Growth and Are Associated with Protection from Clinical Malaria

Atypical B cells upregulate co-stimulatory molecules during malaria and secrete antibodies with T follicular helper cell support

Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites

Broadly inhibitory antibodies against severe malaria virulence proteins

Cryo-EM Reveals the Conformational Epitope of Human Monoclonal Antibody PAM1.4 Broadly Reacting with Polymorphic Malarial Protein VAR2CSA.

Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function.

Target-agnostic identification of human antibodies to Plasmodium falciparum sexual forms reveals cross stage recognition of glutamate-rich repeats

Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype

Sequence Intrinsic Somatic Mutation Mechanisms Contribute to Affinity Maturation of Vrc01-Class Hiv-1 Broadly Neutralizing Antibodies

Mutability and hypermutation antagonize immunoglobulin codon optimality

Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein

Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation

Naturally acquired IgG responses to Plasmodium falciparum do not target the conserved termini of the malaria vaccine candidate merozoite surface protein 2

Production and Modification of Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium Falciparum

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria